Q-omics provides the consensus-scored DYRK1B profile across patient tissues and cancer cell-line models. DYRK1B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, DYRK1B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DYRK1B protein abundance shows 22,528 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BRCA, KIRC, and PDAC as cancer lineages where DYRK1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DYRK1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DYRK1B survival associations across molecular data types. DYRK1B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DYRK1B RNA expression–survival associations across cancer types. High DYRK1B expression shows unfavorable associations in OV, but favorable associations in BRCA, KIRP, UVM, THYM and HNSC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for DYRK1B RNA expression.
This table summarizes DYRK1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DYRK1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DYRK1B shows lower tumor expression in HNSC and higher tumor expression in KIRC, LIHC, KIRP, BLCA and BRCA. The KIRC box plot shows higher DYRK1B RNA expression in tumor versus normal tissue (log2 FC = +0.621, t-test p < 0.001).
This table shows molecular features associated with DYRK1B in patient tissues and cancer cell lines. In patient samples, DYRK1B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, DYRK1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_SCLC.
